Ipsen SA, of Paris, and Telesta Therapeutics Inc. (formerly Bioniche Life Sciences Inc.), of Montreal, inked an exclusive licensing agreement giving Ipsen the right to develop and commercialize MCNA1 to treat high-risk nonmuscle-invasive bladder cancer (NMIBC) outside the U.S., where Telesta is establishing commercial operations, as well as Canada, South Africa, Mexico, South Korea and Japan.